In vivo platelet activation and aspirin responsiveness in type 1 diabetes

Diabetes

Volumn 65, Issue 2, 2016, Pages 503-509

  Zaccardi, Francesco ^a,b   Rizzi, Alessandro ^a   Petrucci, Giovanna ^a   Ciaffardini, Flavia ^a   Tanese, Luigi ^a   Pagliaccia, Francesca ^a   Cavalca, Viviana ^c   Ciminello, Angela ^a   Habib, Aida ^d,e   Squellerio, Isabella ^c   Rizzo, Paola ^a   Tremoli, Elena ^c   Rocca, Bianca ^a   Pitocco, Dario ^a   Patrono, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c CENTRO CARDIOLOGICO MONZINO   (Italy)

^d CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^e AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; CYCLOOXYGENASE 1; INTERLEUKIN 15; INTERLEUKIN 6; PROSTACYCLIN; THROMBOXANE; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTITHROMBOCYTIC AGENT; GLUCOSE BLOOD LEVEL; PROSTAGLANDIN F2 ALPHA; PTGS1 PROTEIN, HUMAN; THROMBOXANE A2;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; URINARY EXCRETION; YOUNG ADULT; ALBUMINURIA; ANALOGS AND DERIVATIVES; ANALYSIS; BIOSYNTHESIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SEX DIFFERENCE; STATISTICAL ANALYSIS; URINE;

ADULT; ALBUMINURIA; ASPIRIN; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE 1; DIABETES MELLITUS, TYPE 1; DINOPROST; EPOPROSTENOL; FEMALE; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MICROVESSELS; MIDDLE AGED; OXIDATIVE STRESS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; SEX FACTORS; THROMBOXANE A2;

EID: 84962449999     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0936     Document Type: Article

References (25)

1. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation 2014; 130: 1110-1130
2. Chiang JL, Kirkman MS, Laffel LM, Peters AL; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014; 37: 2034-2054
3. Livingstone SJ, Levin D, Looker HC, et al.; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015; 313: 37-44
4. Maahs DM, Daniels SR, de Ferranti SD, et al.; American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council for High Blood Pressure Research, and Council on Lifestyle and Cardiometabolic Health. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation 2014; 130: 1532-1558
5. Rydén L, Grant PJ, Anker SD, et al.; ESC Committee for Practice Guidelines. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-3087
6. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494
7. Arthur JF, Shen Y, Chen Y, et al. Exacerbation of glycoprotein VI-dependent platelet responses in a rhesus monkey model of type 1 diabetes. J Diabetes Res 2013; 2013: 370212
8. Stolla MC, Li D, Lu L, Woulfe DS. Enhanced platelet activity and thrombosis in a murine model of type I diabetes are partially insulin-like growth factor 1-dependent and phosphoinositide 3-kinase-dependent. J Thromb Haemost 2013; 11: 919-929
9. Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10: 1220-1230
10. Spectre G, Arnetz L, Östenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost 2011; 106: 491-499
11. Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989; 992: 66-70
12. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997; 17: 2309-2315
13. Brash AR, Jackson EK, Saggese CA, Lawson JA, Oates JA, FitzGerald GA. Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther 1983; 226: 78-87
14. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327
15. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance." J Am Coll Cardiol 2009; 53: 667-677
16. Zaccardi F, Pitocco D, Ghirlanda G. Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab Res Rev 2009; 25: 199-207
17. Chan NN, Vallance P, Colhoun HM. Endothelium-dependent and -independent vascular dysfunction in type 1 diabetes: role of conventional risk factors, sex, and glycemic control. Arterioscler Thromb Vasc Biol 2003; 23: 1048-1054
18. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-1068
19. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539-541
20. Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation 2014; 129: 907-916
21. Codner E. Estrogen and type 1 diabetes mellitus. Pediatr Endocrinol Rev 2008; 6: 228-234
22. Sobrino A, Oviedo PJ, Novella S, et al. Estradiol selectively stimulates endothelial prostacyclin production through estrogen receptor-alpha. J Mol Endocrinol 2010; 44: 237-246
23. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004; 306: 1954-1957
24. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119: 3595-3603
25. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014; 371: 1972-1982